Biomarck Pharmaceuticals Leadership

Dr. Parikh, as cofounder and chief scientific officer, brings more than 40 years of experience in drug discovery and development in a variety of therapeutic areas, fund raising, and licensing to biomark. Dr. Parikh, educated at the University of Zurich in Switzerland, was a founder, chief scientific officer, and vice president of research and development (R&D) for RTP Pharma, a nanotechnology-based drug-delivery company. [RTP Pharma was acquired in 2001 by SkyePharma]. Earlier, he was director of Biochemistry & Biotechnology and director of Extramural Research at Glaxo Inc., and played a leading role in establishing Glaxo’s R&D operation in the Research Triangle, NC from the ground up. Prior to that, he was the head of Molecular Biology Division at Burroughs Wellcome Co. Dr. Parikh has also served as assistant professor of Pharmacology and assistant professor of medicine at Johns Hopkins School of Medicine in Baltimore. He has served on editorial boards of three scientific journals and on scientific and corporate advisory boards of more than 12 biotech companies. In addition to organizing and participating, he has made more than 75 presentations at various national and international scientific conventions. He has published more than 70 peer-reviewed publications and holds more than 25 U.S. patents. .

Dr. Adler is Professor of Cell Biology at NC State University. He obtained his Ph.D. from the University of Vermont in Cell Biology and has published over 100 significant papers. His research has been funded by the National Institutes of Health continuously for over 20 years, and is recognized by his peers as “one of the foremost established and well-respected researchers in the world in the field of airway disease.” He has won numerous awards and was Chair of the NIH Lung Biology and Pathology Study Section (2002-2004), which reviews and prioritizes the great majority of respiratory and pulmonary research grant applications sent to NIH from universities and institutions throughout the country. In 2004, Dr. Adler was honored with the prestigious Alexander Quarles Holladay Medal for Excellence, which is the highest award made by North Carolina State University to a faculty member in recognition for outstanding accomplishments. In 2005, Dr. Adler received the O. Max Gardner Award, the highest faculty award presented by the Board of Governors of the University of North Carolina's 16 member universities. In 2006, the American Thoracic Society presented Dr. Kenneth Adler with an Award for Scientific Accomplishment in recognition of outstanding scientific contributions in basic or clinical research to the understanding, prevention, and treatment of acute or chronic lung diseases.

Dr. Parikh, as cofounder and chief scientific officer, brings more than 40 years of experience in drug discovery and development in a variety of therapeutic areas, fund raising, and licensing to biomark. Dr. Parikh, educated at the University of Zurich in Switzerland, was a founder, chief scientific officer, and vice president of research and development (R&D) for RTP Pharma, a nanotechnology-based drug-delivery company. [RTP Pharma was acquired in 2001 by SkyePharma]. Earlier, he was director of Biochemistry & Biotechnology and director of Extramural Research at Glaxo Inc., and played a leading role in establishing Glaxo’s R&D operation in the Research Triangle, NC from the ground up. Prior to that, he was the head of Molecular Biology Division at Burroughs Wellcome Co. Dr. Parikh has also served as assistant professor of Pharmacology and assistant professor of medicine at Johns Hopkins School of Medicine in Baltimore. He has served on editorial boards of three scientific journals and on scientific and corporate advisory boards of more than 12 biotech companies. In addition to organizing and participating, he has made more than 75 presentations at various national and international scientific conventions. He has published more than 70 peer-reviewed publications and holds more than 25 U.S. patents. .

Dr. Adler is Professor of Cell Biology at NC State University. He obtained his Ph.D. from the University of Vermont in Cell Biology and has published over 100 significant papers. His research has been funded by the National Institutes of Health continuously for over 20 years, and is recognized by his peers as “one of the foremost established and well-respected researchers in the world in the field of airway disease.” He has won numerous awards and was Chair of the NIH Lung Biology and Pathology Study Section (2002-2004), which reviews and prioritizes the great majority of respiratory and pulmonary research grant applications sent to NIH from universities and institutions throughout the country. In 2004, Dr. Adler was honored with the prestigious Alexander Quarles Holladay Medal for Excellence, which is the highest award made by North Carolina State University to a faculty member in recognition for outstanding accomplishments. In 2005, Dr. Adler received the O. Max Gardner Award, the highest faculty award presented by the Board of Governors of the University of North Carolina's 16 member universities. In 2006, the American Thoracic Society presented Dr. Kenneth Adler with an Award for Scientific Accomplishment in recognition of outstanding scientific contributions in basic or clinical research to the understanding, prevention, and treatment of acute or chronic lung diseases.